Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT02397707 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02397707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02397707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
March 24, 2015
Completion date
March 4, 2016
Enrollment
33 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hcv infection